Finance

Lists
AAPG:NASDAQ
Ascentage Pharma Group Internatinl - ADR
$15.36
-0.07%
(-0.010) 1D
Oct 19, 10:50:54 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AAPG...
Open
$15.52
High
$15.65
Low
$15.36
Mkt. cap
1.42B
Avg. vol.
6.98K
Volume
3.35K
52-wk high
$35.86
52-wk low
$14.46
EPS
-$2.36
Shares outstanding
93.74M
No. of employees
828
Open
$15.52
High
$15.65
Low
$15.36
Mkt. cap
1.42B
Avg. vol.
6.98K
Volume
3.35K
52-wk high
$35.86
52-wk low
$14.46
EPS
-$2.36
Shares outstanding
93.74M
No. of employees
828
News stories
From web sources and news partners
About Ascentage Pharma Group Internatinl - ADR
CEODajun Yang
Employees828
Founded2009
Headquarters-
SectorBiotechnology
Websiteascentage.cn
Analyst ratings
Based on 7 analysts giving stock ratings to AAPG in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for AAPG in the last 3 months.
Highest
Current $15.36
$48.00 (+212.50%)
Average
$42.00 (+173.44%)
Lowest
$33.00 (+114.84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Initiated
$46.00
+199.5%
10/15/2026
Silvan Turkcan
Citizens JMP
Buy
Initiated
$35.00
+127.9%
10/13/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$33.00
+114.8%
10/08/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$45.00
+193%
09/02/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$48.00
+212.5%
08/20/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
08/21/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$45.00
+193%
08/21/2026
Biren Amin
Piper Sandler
Buy
Maintained
$48.00
+212.5%
06/01/2026
James Shin
Deutsche Bank
Buy
Initiated
$40.00
+160.4%
04/24/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$45.00
+193%
03/27/2026
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
170.21M
170.21M
151.11M
151.11M
Cost of goods sold
13.64M
13.64M
5.86M
5.86M
Cost of revenue
13.64M
13.64M
5.86M
5.86M
Research and development expenses
304.44M
304.44M
348.73M
348.73M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
181.22M
181.22M
172.64M
172.64M
Operating expense
485.67M
485.67M
521.37M
521.37M
Total operating expenses
499.31M
499.31M
527.23M
527.23M
Operating income
-329.10M
-329.10M
-376.13M
-376.13M
Other non operating income
-2.99M
-2.99M
-30.14M
-30.14M
EBT including unusual items
-325.37M
-325.37M
-401.69M
-401.69M
EBT excluding unusual items
-324.79M
-324.79M
-401.69M
-401.69M
Income tax expense
714.00K
714.00K
6.81M
6.81M
Effective tax rate
-0.22%
-0.22%
-1.70%
-1.70%
Other operating expenses
-
-
-
-
Net income
-326.00M
-326.00M
-408.35M
-408.35M
Net profit margin
-191.53%
-191.53%
-270.24%
-270.24%
Earnings per share
-
-
-
-
Interest and investment income
25.36M
25.36M
18.00M
18.00M
Interest expense
-13.14M
-13.14M
-13.41M
-13.41M
Net interest expenses
12.22M
12.22M
4.59M
4.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-310.96M
-310.96M
-356.97M
-356.97M
Gain or loss from assets sale
-333.50K
-333.50K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps